Ultomiris approved in the US for NMOSD
25 March 2024 Ultomiris approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD) First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+ NMOSD the potential to live relapse-free Unprecedented relapse risk reduction observed in CHAMPION-NMOSD trial underscores how Ultomiris may redefine patient journey for rare neurological disease Ultomiris (ravulizumab-cwvz) has been approved in the United States (US) as the first and only long-acting C5 complement inhibitor for the treatment of adult patients with anti-